BlossomHill 制药
BLSM
13.94
-1.04
-6.94%
BlossomHill 制药
US · BLSM
#3711 按市值排名
上市于 2026
13.94
-1.04
-6.94%
实时 - 追踪5344个代码 - 心跳于405秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了11家。
- 机构持股总比例上升了42.2个百分点。
机构持股
- 机构持股比例
- 42.20% +42.20pp
- 机构数量
- 11 +11
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund21.34%
Hedge Fund11.37%
Individual/Insider7.89%
Private Company5.39%
Mutual Fund4.09%
Other49.92%
主要股东 截至 2026-08-10
Cormorant Asset Management, LP
11.37% · 3.61M 股
OrbiMed Advisors LLC
8.54% · 2.71M 股
Perceptive Advisors LLC
5.69% · 1.81M 股
The Li and Cui Family Trust
5.39% · 1.71M 股
Vivo Capital, LLC
5.29% · 1.68M 股
Janus Henderson Group plc
3.57% · 1.13M 股
Jingrong Cui
3.36% · 1.07M 股
Jingrong Jean Cui
3.36% · 1.07M 股
Brahma Capital
1.82% · 578.52K 股
Vincent Liptak
0.42% · 134.10K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪34份申报 · 19次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Cormorant Asset Management, LP | -- | 11.37% |
| Jingrong Cui | -- | 3.36% |
| Vincent Liptak | General Counsel & Executive VP | 0.42% |
| Yishan Li | Co-Founder & Executive Chairperson | 0.39% |
| Sheila Gujrathi | Lead Independent Director | 0.28% |
| Geoff Oxnard | Chief Medical Officer & Executive VP | 0.06% |
| John Schmid | Independent Director | 0.02% |
| Jason Keyes | Chief Financial Officer | 0.00% |
| OrbiMed Advisors LLC | -- | -- |
| Carl Gordon | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-09 | OrbiMed Advisors LLC | -- | Open Market Acquisition | +625,000 | $16.00 |
| 2026-08-09 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +2,089,279 | -- |
| 2026-08-09 | John Schmid | Independent Director | Open Market Acquisition | +6,000 | $16.00 |
| 2026-08-09 | Yishan Li | Co-Founder & Executive Chairperson | Derivative Exercise and Retained | +124,779 | -- |
| 2026-08-09 | Brahma Capital | -- | Derivative Exercise and Retained | +578,524 | -- |
| 2026-08-09 | Cormorant Asset Management, LP | -- | Open Market Acquisition | +312,500 | $16.00 |
| 2026-08-09 | Cormorant Asset Management, LP | -- | Derivative Exercise and Retained | +3,301,534 | -- |
| 2026-08-09 | Jason Keyes | Chief Financial Officer | Open Market Acquisition | +700 | $16.00 |
| 2026-08-09 | Vincent Liptak | General Counsel & Executive VP | Open Market Acquisition | +4,700 | $15.80–16.00 |
| 2026-08-09 | Vincent Liptak | General Counsel & Executive VP | Derivative Exercise and Retained | +22,687 | -- |
| 2026-08-09 | The Li and Cui Family Trust | -- | Derivative Exercise and Retained | +1,714,117 | -- |
| 2026-08-05 | Carl Gordon | Independent Director | Other Derivative Acquisition | +23,904 | $16.00 |
| 2026-08-05 | John Schmid | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Yishan Li | Co-Founder & Executive Chairperson | Other Derivative Acquisition | +112,701 | $16.00 |
| 2026-08-05 | Yishan Li | Co-Founder & Executive Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sheila Gujrathi | Lead Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Cormorant Asset Management, LP | -- | Other Derivative Acquisition | +23,904 | $16.00 |
| 2026-08-05 | Cormorant Asset Management, LP | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sundeep Agrawal | Independent Director | Other Derivative Acquisition | +23,904 | $16.00 |
| 2026-08-05 | Sundeep Agrawal | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
BlossomHill 制药 讨论区 0 条评论